Company Profile
Updated: 26-OCT-09BioPhausia AB
International public company
Blasieholmsgatan 2, Stockholm, S-111 48, Sweden
()46 08 407 64 30, 46 08 407 64 39 fax, http://www.biophausia.se
Primary SIC: Pharmaceutical Preparations, Primary NAICS: Pharmaceutical Preparation Manufacturing
Description: Manufacturing: Research and marketing company with central competence in micro-circulation, macromolecules and biopolymers
View this company profile - Now for a Limited Time, try Goliath Company Profiles
Free for 3 Days!
BioPhausia AB-Company Report.
M2 Presswire; 2/8/2009; 524 words; ...8 February 2009-www.companiesandmarkets.com: BioPhausia AB-Company Report(C)1994-2009 M2 COMMUNICATIONS...www.companiesandmarkets.com adds new report: BioPhausia AB-Company Report Private Company Reports provide up...
BioPhausia AB posts Q3 operating profit of SEK21m.(Financial report)
Nordic Business Report; 11/21/2008; 557 words; NORDIC BUSINESS REPORT-21 November 2008-BioPhausia AB posts Q3 operating profit of SEK21m(C)1994-2008...www.m2.com Swedish speciality pharma company BioPhausia AB (OMX Stockholm:BIOP) issued its third quarter report...
BioPhausia AB completes SEK535m acquisition of prescription pharmaceuticals portfolio from AstraZeneca.
Nordic Business Report; 6/30/2008; 553 words; NORDIC BUSINESS REPORT-30 June 2008-BioPhausia AB completes SEK535m acquisition of prescription pharmaceuticals...www.m2.com Swedish speciality pharma company BioPhausia AB (OMX Stockholm: BIOP) said on Monday (30 June...
Swedish speciality pharma company BioPhausia AB acquires drug portfolio from AstraZeneca.
Nordic Business Report; 5/26/2008; 505 words; ...REPORT-26 May 2008-Swedish speciality pharma company BioPhausia AB acquires drug portfolio from AstraZeneca(C)1994...www.m2.com Swedish speciality pharma company BioPhausia AB (OMX Stockholm:BIOP) said on Monday (26 May) that...
Press Release from Artimplant's Nomination Committee.
Business Wire; 3/11/2008; 670 words; ...clinical development and commercialization of pharmaceutical products. Mats Lindquist is a non executive Board member of BioPhausia AB. About Artimplant Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery...
Recent News Articles
- BioPhausia AB-Company Report.
M2 Presswire - February 08, 2009 - BioPhausia AB posts Q3 operating profit of SEK21m.(Financial report)
Nordic Business Report - November 21, 2008 - BioPhausia AB completes SEK535m acquisition of prescription pharmaceuticals portfolio from AstraZeneca.
Nordic Business Report - June 30, 2008 - Swedish speciality pharma company BioPhausia AB acquires drug portfolio from AstraZeneca.
Nordic Business Report - May 26, 2008
Why Purchase This Company Profile?
- Sales prospecting
- Competitive analysis
- Vendor & supplier evaluation
- Customer evaluation and analysis
- Strategic planning